Brief: Moleculin Doses First Patient In Pivotal, Adaptive Phase 3 Miracle Trial
01/04/2025 13:32
April 1 (Reuters) - Moleculin Biotech Inc MBRX.O: MOLECULIN DOSES FIRST PATIENT IN PIVOTAL, ADAPTIVE PHASE 3 MIRACLE TRIAL MOLECULIN BIOTECH INC - PRELIMINARY DATA FROM FIRST 45 SUBJECTS EXPECTED IN H2 2025 Source text: ID:nGNX9YtFyb Further company coverage: MBRX.O (((( Reuters.briefs@thomsonreuters.com ;));))
Recent news on Moleculin Biotech
See all newsMoleculin Biotech Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Moleculin Secures Australian Patent For Annamycin Formulation Technology
Moleculin Biotech Inc expected to post a loss of $8.87 a share - Earnings Preview
Brief: Moleculin Biotech Completes Dosing In Part A Of Miracle Trial Data Readout On Track For Q1 2027
NASDAQ RESUMED AT 09:00 AM